Replies to post #110844 on Biotech Values

[mcbio]

Re: Xgeva results/XL184

I wonder if the results reported for Xgeva in this trial regarding prevention of bone mets may cause EXEL to be more inclined to ultimately focus the development of XL184 on treating bone mets, as opposed to prevention, via trying to demonstrate a survival advantage and/or pain benefit? They could also still focus on a pain benefit in HRPC patients who haven't experienced bone mets if they weren't inclined to otherwise also try to show a benefit for XL184 in preventing bone mets.